Becton Dickinson Acquires Edwards Lifesciences' Critical Care Unit for $4.2 Billion

The acquisition will enhance BD's portfolio with advanced monitoring technologies and AI-enabled clinical tools.

The $4.2 billion deal will be funded by $1 billion in cash and $3.2 billion in new debt.
Edwards Lifesciences' Critical Care unit generated over $900 million in revenue last year.
The unit, with 4,500 employees, will continue to operate as a separate business under BD.
The transaction is expected to close by the end of the year.
BD's portfolio will expand with Edwards' innovative monitoring technologies and AI tools.